YMYuichiro Maruyama

Yuichiro Maruyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuichiro Maruyama has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after surgical treatment

    by Yuichiro Maruyama, Yoshiki Naito, Yoshinobu Okabe, Yohei Nakama, Daisuke Muroya, Shoichiro Arai, Goichi Nakayama, Masanori Akashi, Ryuichi Kawahara, Hiroto Ishikawa, et al.

  • Torsion of the gallbladder, localized in right subphrenic space in a patient with liver cirrhosis

    by Yuichiro Maruyama, Yuya Tanaka, Masafumi Yasunaga, Kei Ogata, Hiroyuki Tanaka, Yoshito Akagi, Koji Okuda


    • 1 November 2014
      • Vol. 41  (12) , 1518-20

    [A case of postoperative recurrent hilar cholangiocarcinoma in the lower bile duct treated with pancreatoduodenectomy].

    by Ryuichi Kawahara, Masahiko Tanigawa, Hiroyuki Horiuchi, Kenjiro Takahashi, Takahisa Shirahama, Youhei Nakama, Hiroaki Takagi, Yusuke Hirakawa, Yuichiro Maruyama, Hisamune Sakai, et al.

    When surgery is selected to treat postoperative recurrent hilar cholangiocarcinoma in the intrapancreatic bile duct, attention should be paid to the following: 1 ) technical resectability of the lesion, 2) reconstruction, and 3) high risk of complications. Eight cases, including the present case, of pancreatoduodenectomy (PD) for postoperative recurrent hilar cholangiocarcinoma in the intrapancreatic bile duct have been reported thus far. In October 2009, a 73-year-old man noticed that his stools were gray and visited a physician. He was diagnosed with cholangiocarcinoma on close examination and underwent left hepatic and caudate lobectomy in January 2010. After the surgery, he was treated with TS-1 (80 mg) and followed up at the outpatient clinic of our hospital. In July 2013, he was diagnosed with cancer of the lower bile duct and was admitted for surgery. The first and second pathological findings were carcinoma of the bile duct and papillary adenocarcinoma, respectively. The findings from the immunostaining were also inconsistent. The histopathological examination result suggested multicentric recurrence. The surgery was highly invasive, increasing the patient's risk of complications, in addition to the presence of postoperative adhesion. Therefore, surgery may be an important option for cases of localized recurrence but not for multicentric recurrence.


  • Open Access

    Perioperative Challenges and Surgical Treatment of Large Simple, and Infectious Liver Cyst - A 12-Year Experience

    by Yuichiro Maruyama, Koji Okuda, Toshiro Ogata, Masafumi Yasunaga, Hiroto Ishikawa, Yusuke Hirakawa, Kenjiro Fukuyo, Hiroyuki Horiuchi, Osamu Nakashima, Hisafumi Kinoshita

    Cystic lesions of the liver consist of a heterogeneous group of disorders that can present diagnostic and therapeutic challenges. A retrospective review of all medical records of adult patients diagnosed with large (>7 cm) cystic lesions of the liver between January 2000 and December 2011, at Kurume University Hospital. Cases with polycystic disease were excluded. Twenty three patients were identified. The mean size was 13.9 cm (range, 7-22cm). The majority of simple cysts were found in women (females: males, 2: 21). In 19 patients, the cyst was removed surgically by wide deroofing (laparoscopically in 16 cases, combined with ethanol sclerotherapy in 13 cases). Infection of the liver cyst occurred in one patient, who later underwent central bi-segmentectomy. Simple large cysts of the liver can be successfully treated by laparoscopic deroofing and alcohol sclerotherapy. Large hepatic cyst considered to need drainage should be removed surgically to avoid possible infection.


    • 10 May 2012
      • Vol. 13  (3) , 296-300

    Metastatic pulmonary adenocarcinoma 13 years after curative resection for pancreatic cancer: report of a case and review of Japanese literature.

    by Yuhei Kitasato, Masamichi Nakayama, Gen Akasu, Munehiro Yoshitomi, Kazuhiro Mikagi, Yuichiro Maruyama, Ryuichi Kawahara, Hiroto Ishikawa, Toru Hisaka, Masafumi Yasunaga, et al.

    For the majority of patients, ductal adenocarcinoma of the pancreas remains a lethal disease. Currently, surgical extirpation for localized disease offers the only chance for long-term survival. We report a patient who underwent successful resection of isolated lung metastasis occurring 13 years after pancreatic cancer resection. A 59-year-old woman underwent distal pancreatectomy for pancreatic cancer 13 years previously, followed by adjuvant chemotherapy, and was followed-up at the outpatient clinic of a local hospital. From around June 2010, she noticed bloody sputum, so she visited a local hospital. Since her chest X-ray and CT revealed a 1.5 cm mass shadow in the segment 10 of her right lung and she was referred to the Respiratory Disease Center of our hospital. As a result of through examinations, she was strongly suspected of having lung metastasis of pancreatic cancer, and underwent partial pneumonectomy. Postoperative histopathological examination of the resected specimen was consistent with lung metastasis of pancreatic cancer. She is still alive and currently receives third line of chemotherapy. Patients who have achieved long-term survival after pancreatic cancer resection and can tolerate surgery may benefit from resection of a lung metastasis of pancreatic cancer in terms of survival, if it controls the metastasis.


    • 1 April 2011
      • Vol. 38  (4) , 585-9

    [Liver histology and surgical outcomes after preoperative chemotherapy in colorectal cancer liver metastases].

    by Toru Hisaka, Hiroyuki Horiuchi, Shinji Uchida, Hiroto Ishikawa, Yutaka Ogata, Yoshito Akagi, Nobuya Ishibashi, Ryuichi Kawahara, Yuichiro Maruyama, Kazuhiro Mikagi, et al.

    We aimed to assess hepatic histopathological responses to preoperative chemotherapy in patients with colorectal liver metastasis. We selected all patients(n=34)with colorectal liver metastases between September 2006 and March 2009. The preoperative chemotherapy group was significantly associated with tumor regression, inflammatory response, sinusoidal dilatation compared with non-chemotherapy group. There was no difference in the rate of postoperative complications and hospital stay. Prolonged preoperative systemic chemotherapy alters liver parenchyma, but it does not increase postoperative complications. This should be taken into consideration before deciding a major liver resection in patients who have received preoperative chemotherapy.

    • 1 November 2008
      • Vol. 35  (12) , 2129-31

    [A case of intraluminal/external irradiation, chemotherapy and T-tube stent treatment for the local recurrence of the postoperative four-year bile duct cancer].

    by Munehiro Yoshitomi, Hiroyuki Horiuchi, Ryuichi Kawahara, Shinji Uchida, Tohru Hisaka, Takenori Sakai, Yuichiro Maruyama, Hisafumi Kinoshita

    The patient was a 73-year-old man. In 2001, PPPD was performed. After confirmation of an expanded intrahepatic bile duct and anastomic stenosis in July 2005, PTBD was performed into the B3. Adenocarcinoma was detected with bile cytodiagnosis, and was diagnosed as a recurrence of the left bile-duct anastomotic site. Under the informed consent, chemo-radiotherapy was performed in addition to beam radiotherapy (30 Gy) in September 2005. Then we performed an intracavitary irradiation at 25 Gy. UFT (200 mg) was administered along with the radiation therapies. After that, an internal fistularization due to the T-tube was done. Liver metastasis was confirmed by abdominal CT in 2006. We started administering of GEM (600 mg/body) every other week after the recurrence of the bile duct cancer. The patient had survived for 24 months from the recurrence. We report a good result of the recurrent bile duct cancer treated with combined modality therapy.